Dark Horse Fovista Challenges Regeneron's Eylea in Wet AMD
By Catherine Shaffer
Thursday, June 14, 2012
Stellar Phase IIb results reported by Ophthotech Corp. for Fovista have harshed Regeneron Pharmaceuticals Inc.'s mellow just six weeks after the highly successful launch of competing product Eylea (aflibercept opthalmic solution).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.